Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis

Abdul Hakkim(Max Planck Society), Barbara G. Fürnrohr(Center for Clinical Research (United States)), Kerstin Amann(Friedrich-Alexander-Universität Erlangen-Nürnberg), Britta Laube(Max Planck Institute for Infection Biology), Ulrike Abu Abed(Max Planck Society), Volker Brinkmann(Max Planck Institute for Infection Biology), Martin Herrmann(Friedrich-Alexander-Universität Erlangen-Nürnberg), Reinhard Voll(Friedrich-Alexander-Universität Erlangen-Nürnberg), Arturo Zychlinsky(Max Planck Society)
Proceedings of the National Academy of Sciences
May 3, 2010
Cited by 1,447Open Access
Full Text

Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease in which patients develop autoantibodies to DNA, histones, and often to neutrophil proteins. These form immune complexes that are pathogenic and may cause lupus nephritis. In SLE patients, infections can initiate flares and are a major cause of mortality. Neutrophils respond to infections and release extracellular traps (NETs), which are antimicrobial and are made of DNA, histones, and neutrophil proteins. The timely removal of NETs may be crucial for tissue homeostasis to avoid presentation of self-antigens. We tested the hypothesis that SLE patients cannot clear NETs, contributing to the pathogenesis of lupus nephritis. Here we show that serum endonuclease DNase1 is essential for disassembly of NETs. Interestingly, a subset of SLE patients' sera degraded NETs poorly. Two mechanisms caused this impaired NET degradation: (i) the presence of DNase1 inhibitors or (ii) anti-NET antibodies prevented DNase1 access to NETs. Impairment of DNase1 function and failure to dismantle NETs correlated with kidney involvement. Hence, identification of SLE patients who cannot dismantle NETs might be a useful indicator of renal involvement. Moreover, NETs might represent a therapeutic target in SLE.


Related Papers

No related papers found

Powered by citation graph analysis